Approximately 90% of cervical carcinomas are causally linked to infections with high-risk human papillomaviruses (HPVs), whose oncogenicity has been assigned to the continued expression of two early genes, E6 and E7. Reversal of the transformed phenotype by inhibiting E6/E7 gene expression therefore provides a suitable goal for future tumor therapy. Using recombinant adeno-associated virus type 2 (AAV-2) vectors, two types of therapeutic genes were expressed in cervical carcinoma cells with the aim of suppressing the E6/E7 oncogenes: (a) antisense E6/E7 and ribozyme genes and (b) the monocyte chemoattractant protein-1 (MCP-1) gene encoding MCP-1. Previous studies have shown that the MCP-1 protein is able to indirectly repress E6/E7 gene expression and is consistently absent in tumorigenic HPV-positive cervical carcinoma cell lines. Here, the effect of these therapeutic genes on tumor formation is analyzed in nude mice after ex vivo gene transfer into a HPV16-or HPV18-positive cervical carcinoma cell line (HeLa or SiHa, respectively). Whereas AAV-2 vector-mediated transfer of antisense or even ribozyme genes did not significantly influence tumor formation from implanted SiHa cells, the transfer and expression of human MCP-1 strongly inhibited the development of tumors derived from either HeLa or SiHa cells. Similar results were also obtained after in vivo delivery of these genes into SiHa-derived tumors. This suggests that transfer of therapeutic genes mediating a systemic effect via recombinant AAV-2 vectors offers a promising approach for the development of gene therapies directed against papillomavirus-induced human cancers. Cancer Gene Therapy (2000) 7, 766 -777
P ersistent infections by "high risk" human papillomavirus (HPV) types such as HPV16 and HPV18 is regarded as the main risk factor involved in the development of cervical cancer (reviewed in Refs. 1 and 2). The oncogenic function of these HPV types has been primarily attributed to the expression of two early genes, E6 and E7, which induce cell cycle progression by labilization of p53 3 and sequestration of retinoblastoma protein, 4 cellular immortalization, 5 and chromosomal aberrations. 6 Several lines of evidence show that expression of these transforming genes has to be continuous to maintain the tumorigenic phenotype of cervical cancer cells infected with the high-risk HPV types. Inhibition of E6 and E7 by complementary antisense transcripts led to reduced growth rates, loss of the transformed phenotype of cervical and oral carcinoma cell lines, [7] [8] [9] and inhibition of tumor formation in an animal model. 7, 10 Antisense E6 and E7 oligonucleotides also showed an antiproliferative effect in primary tumor explants. 11 Recently, it was shown that expression of an anti-E6 hairpin ribozyme in cis led to a reduced growth rate of human keratinocytes and prevented immortalization with HPV E6/E7 genes. 12 From animal papillomavirus experiments and from studies in humans, there is good evidence that the immune system is also involved in the control of papillomavirus infections both in their primary manifestation and in the progression toward malignancies. 13, 14 For example, advanced cervical intraepithelial neoplasias are immunohistochemically characterized by a significant reduction in intraepithelial macrophages, 15 Langerhans cells, 16 and T lymphocytes. 17 Depletion of these immunoregulatory cells may in turn dysregulate the network of inflammatory response cytokines, which normally controls persistent HPV infection. 14 In addition, it has been shown that expression of the JE gene, which encodes monocyte chemoattractant protein-1 (MCP-1), is consistently absent in tumorigenic HPV-positive cervical carcinoma cell lines, although the endogenous gene is present and not structurally rearranged. 18 MCP-1 expression can be restored by fusion of cervical carcinoma cells with human fibroblasts or keratinocytes, leading to non-malignant cell hybrids, whereas this expression is down-regulated in tumorigenic revertants. 18 Cocultivation of cervical carcinoma cells with activated human macrophages showed that in nontumorigenic cell hybrids, the viral oncogenes E6 and E7 were selectively down-regulated, while their expression was not affected in tumorigenic counterparts. A dysregulation of MCP-1 expression in high-grade lesions compared with low-grade lesions was also observed by in situ hybridization in histologically distinct stages of cervical intraepithelial neoplasias, 19, 20 indicating that a change in MCP-1 expression may represent an important step during HPV-linked carcinogenesis.
The relatively detailed knowledge of the etiology of cervical carcinomas provides a basis for specific gene therapy approaches. A major focus has so far been put on the down-regulation of the transforming genes E6 and E7. Based on the proliferation-inhibiting effects of HPV16/HPV18 antisense E6 and E7 DNAs, several therapeutic approaches using these DNAs have been developed. Treatment of CaSki and SiHa cells with phosphorothioate oligonucleotides against HPV16 E6 and E7 not only reduced cell proliferation in vitro but also led to a reduction in the weight of tumors derived from SiHa cells implanted into nude mice.
9,21 Expression of antisense E6/E7 genes using adenoviral gene transfer resulted in a strong inhibition of SiHa cell proliferation and a complete suppression of tumor formation after ex vivo application. 22 Liposome-mediated transfer of genes efficiently expressing antisense E7 induced tumor cell apoptosis and an antitumoral immune response that was augmented by codelivery of interleukin-12 cytokine genes. 23 Adeno-associated virus type 2 (AAV-2)-derived vectors have gained increasing acceptance for the delivery of genes to cure genetic disorders because of their low immunogenicity, long-term expression power, and apathogenicity according to our current knowledge. This vector system has also been used successfully in preclinical cancer gene therapy protocols in a number of recent studies, 24 -26 and it has been proposed as a suitable vector system for the delivery of antisense RNA. 27 We have tested the ability of recombinant AAV-2 (rAAV-2) vectors to deliver selected catalytic and non-catalytic antisense genes to cervical cancer cells and analyzed their effect on tumor formation. We also constructed rAAV-2 vectors expressing the MCP-1 protein and analyzed their antitumoral efficacy in nude mice tumor models ex vivo and in vivo. Although the expression of HPV16 E6 and E7 antisense constructs using AAV vectors had no measurable effect, expression of MCP-1 led to a significant reduction in tumor growth.
MATERIALS AND METHODS

Cell lines and culture conditions
The human cervical cancer cell lines C33a, SiHa, CaSki, and HeLa were maintained in Dulbecco's modified Eagle's medium (DMEM) (BRL, Karlsruhe, Germany) supplemented with 10% fetal calf sera (FCS), 1% penicillin, and 1% streptomycin.
rAAV-2 plasmids
The vector plasmids pAV-CMV and pAV-K14 containing the two AAV-2 inverted terminal repeats (ITRs) and the human cytomegalovirus (CMV) or cytokeratin K14 promoter, respectively, were derived from psub201 ϩ28 as follows. First, a DraIII/BamHI fragment comprising a poly(A) signal as well as the simian virus 40 (SV40) poly(A) signal and splice site from pGL-2 (Promega, Mannheim, Germany) was blunt-ended and inserted into digested XbaI and blunt-ended psub201 ϩ , yielding the plasmid pAV. Before this, the luciferase gene present on pGL-2 had been deleted through digestion of pGL-2 with HindIII and EcoNI, followed by religation of the remaining blunt-ended plasmid fragment. Next, a 877-bp HincII/AvaII fragment comprising the human CMV-IE promoter 29 together with a FspI/EcoRI fragment (1460 bp) from the human poly-(ADP-ribose) polymerase (PARP) gene was blunt-ended and cloned into the unique KpnI site (blunt ended) located between the two poly(A) signals of pAV, resulting in the plasmid pAV-CMV (Fig 1A) . For construction of pAV-K14, the cytokeratin K14 promoter 30 was inserted as a 1946-bp AvaI fragment into the KpnI site of pAV (both DNA fragments were blunt ended). Both pAV-CMV and pAV-K14 contain the multiple cloning site of pGL-2 to allow straight forward insertion of genes of interest (Fig 1A) .
E6 and E7 antisense DNAs were generated through polymerase chain reaction amplification of fragments (depicted in Fig 1B) from cDNA clones representing either the unspliced HPV16 E6/E7 transcript or the spliced transcript (E6*/E7), which results from deletion of an intron between positions 226 and 409. 31 The two antisense DNAs were amplified using primers that allowed their cloning as a HindIII/PstI (E6/E7) or EcoRI/PstI (E6*/E7) fragment into the appropriately digested plasmid pBluescript SK ϩ (Stratagene, Heidelberg, Germany). Templates for the asymmetric ribozymes Rz1, Rz6, and Rz4 were prepared using primers containing hammerhead sequences 32 together with a 20-nucleotide long fragment complementary to the E6/E7 or E6*/E7 transcript, starting at nucleotides 292, 477, or 725, respectively. The 5Ј primers started at positions 94 (Rz1 and Rz6) or 533 (Rz4). All primers were designed to provide HindIII and SacI restriction sites to allow subsequent cloning of the various polymerase chain reaction products into pBluescript SK ϩ . From the resulting plasmids, all antisense and ribozyme constructs were subcloned as blunt-ended SacI/ClaI-fragments into the unique KpnI site (blunt ended) of pAV-CMV or pAV-K14.
In addition, a 740-bp XhoI fragment from pGEM-hJE34 (kindly provided by F. Rösl, German Cancer Research Center, Heidelberg, Germany) comprising the cDNA for human MCP-1 was cloned into the XhoI linearized plasmids pAV-CMV and pAV-K14. The resulting AAV-2 vector constructs were denoted pAV-CMV-MCP-1 and pAV-K14-MCP-1 (see Fig 3A) .
Northern blot analyses
Total cellular RNA from 5 ϫ 10 6 cells was extracted using a common guanidine isothiocyanate lysis protocol. 33 Equal amounts of RNA (based on the optical density at 260 nm) were electrophoretically separated in a 1% agarose-formaldehyde gel (50 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.8) and 1 mM ethylenediaminetetraacetic acid (EDTA)) and transferred onto a nylon membrane (Gene-Screen Plus, DuPont New England Nuclear, Boston, Mass) via capillary blotting in 25 mM phosphate buffer (pH 6.8) overnight. To detect MCP-1 transcripts, the nylon filter was prehybridized for 2 hours at 42°C and then hybridized with a MCP-1-specific probe (XhoI fragment (0.74 kb) of pGEMhJE34, labeled with 32 P via random priming 34 at 42°C overnight in hybridization solution (7% (wt/vol) sodium dodecyl sulfate (SDS), 0.125 M sodium phosphate buffer (pH 7.2), 0.25 M NaCl, 1 mM EDTA, and 45% (vol/vol) formamide)). The filter was washed four times in 2ϫ standard saline citrate (SSC) (1ϫ SSC is 0.15 mM NaCl, 15 mM sodium citrate) and 0.1% SDS at 42°C for 5 minutes and subsequently washed twice with 0.2ϫ SSC and 0.1% SDS at 68°C for 30 minutes each. The filter was air dried and autoradiographed at room temperature using Kodak X-Omat XAR-5 films (Kodak, Rochester, NY).
Proliferation assay
A double immunofluorescence proliferation assay 35 was used to analyze the influence of AAV-2 vector constructs containing HPV16 E6 and E7 antisense and ribozyme genes on the proliferation of cervical carcinoma cells. A 1:1 mixture of the vector constructs (1 mg/mL) together with purified rabbit immunoglobulin G (IgG) (1 mg/mL) was microinjected into the nuclei of SiHa, CaSki, or C33a cells. (The cells were seeded 20 hours before injection to allow formation of a semiconfluent ϩ ; pA1 (polyadenylation signal) from pGL-2, PARP (fragment of human PARP), and pA2 (polyadenylation signal from SV40). The different fragments (i.e., the E6/E7, E6*/E7, or ribozyme genes (Rz1, Rz6, and Rz4)) were cloned in an antisense orientation behind the CMV promoters (P CMV ) or cytokeratin 14 promoters (P K14 ), respectively, of vectors pAV-CMV or pAV-K14 (for details see Materials and Methods). monolayer.) In the 100 -200 nuclear injections carried out with each sample, an efficiency of ϳ70% was achieved (as estimated by eye). The dishes were returned to the incubator within 30 minutes. Newly replicated DNA was then analyzed using a bromodeoxyuridine (BrdU)-labeling protocol (Amersham Life Science, Braunschweig, Germany). Labeling of cultured cells was started at 6 hours postinjection by adding BrdU-containing medium to the cells and was continued for 14 hours. The cells were fixed using methanol followed by acetone at 4°C for 10 minutes each. Proliferating cells were detected via immunofluorescence staining of incorporated BrdU using a murine monoclonal antibody (Ab) recognizing BrdU (diluted 1/100 in water containing nuclease to enhance the Ab's access to the DNA, all reagents were part of the BrdU-labeling kit), followed by a fluorescein-coupled goat anti-mouse secondary Ab. The total number of injected cells was determined using a rhodamine-coupled goat anti-rabbit IgG Ab. Both secondary Abs (Dianova, Hamburg, Germany) were diluted 1/50 in 1% bovine serum albumin in phosphate-buffered saline (PBS) (18 mM Na 2 HPO 4 , 10 mM KH 2 PO 4 , and 125 mM NaCl). The numbers of injected or noninjected cells, respectively, that had entered S phase were counted; in addition, the percentage of each fraction was calculated.
Production of rAAV particles
AAV-2 vector particles were produced via cotransfection of 293 cells with one of the vector constructs and the packaging plasmid pDG, as described recently. 36 The cells were harvested at 48 hours posttransfection, subjected to repeated freezethawing, and centrifuged at 5000 ϫ g for 10 minutes to remove cell debris. Typical rAAV titers in the cleared supernatant were 10 6 -10 7 infectious units (IU)/mL, as determined by replication assays. 36 
Concentration of vector particles
Concentration of rAAV particles was achieved through column chromatography using sulfonated cellulose (cellufine sulfate) as the matrix. 37 The cleared supernatant from 10 14-cm diameter dishes was slowly applied overnight to the column (2 mL column volume; Amicon, Witten, Germany). After washing with PBS, the AAV-2 vector particles were eluted using 10 mM phosphate buffer (pH 7.2) containing 1 M NaCl. Fractions of 2 mL were collected, with the majority of particles being recovered in the first two fractions. For further purification and concentration, all fractions containing vector particles were pooled and centrifuged through a sucrose cushion. Typically, such a cushion was formed by underlaying 450 L of 30% sucrose in TE (10 mM tris(hydroxymethyl)aminomethane), 1 mM EDTA (pH 7.6)) with 450 L of 50% sucrose in TE. The pooled fractions containing the eluted particles (in 1 M NaCl, ϳ3 mL) were loaded on top of the sucrose cushion and centrifuged at 45,000 rpm (273,000 ϫ g) for 2.5 hours at 4°C using a SW 60 rotor (Kontron, Neufahrn, Germany). The pelleted particles were resuspended in 0.5 mL of Opti-MEM (BRL) supplemented with 1% penicillin and streptomycin.
Tumorigenicity assay
For ex vivo treatment, SiHa or HeLa cells were infected with purified recombinant viruses at a multiplicity of infection (MOI) of 2, 10, or 25 in DMEM supplemented with 2% FCS. At 8 hours postinfection, the inoculum was removed and replaced with fresh DMEM supplemented with 10% FCS. On the following day, infected cells were harvested via trypsinization, rinsed twice with PBS, and resuspended in Hank's buffer. For each injection, 2 ϫ 10 6 HeLa cells or 5 ϫ 10 6 SiHa cells in a volume of 0.15 mL in Hank's buffer were injected subcutaneously into a nude (nu/nu) female mouse (ϳ5-6 weeks old). The tumors were measured twice a week using calipers in three perpendicular diameters over a period of 25 days for HeLaderived tumors and 60 days for SiHa-derived tumors. The tumor volume was calculated according to the following formula: 1/6 ϫ a ϫ b ϫ c, where a, b, and c represent the tumor's perpendicular diameters. For in vivo treatment, tumors were established in nude (nu/nu) mice through subcutaneous injection of 5 ϫ 10 6 SiHa cells into the shoulder pad. After 3 weeks, when tumors had reached a volume of between 70 and 160 mm 3 , rAAV-2 expressing MCP-1 was directly injected at three sites, with a total of 5 ϫ 10 6 infectious particles per tumor, followed by a second injection of 1 ϫ 10 7 particles expressing either MCP-1 or Rz6 5 days later. As a control, animals received a single mock injection of 50 L of Hank's buffer or rAAV expressing antisense MCP-1. Tumor volume was measured twice a week up to 18 days posttreatment.
Enzyme-linked immunosorbent assay (ELISA) test and chemotaxis assay
SiHa cells (5 ϫ 10
3 ) were plated in 96-well plates and infected with purified rAAV-2 MCP-1 virus particles at an MOI of 20, 50, 100, or 400 in DMEM supplemented with 2% FCS. At 16 hours postinfection, the inoculum was removed and replaced with 300 L of fresh DMEM supplemented with 2% FCS. Cell supernatants were collected 1, 2 or 5 days later and tested for the presence of MCP-1 using a commercially available ELISA (R&D Systems, Wiesbaden-Nordenstadt, Germany).
The chemotactic activity of MCP-1 was measured using a chemotaxis assay. Human monocytes were isolated via elutriation in a JE-6 rotor (Beckmann, Palo Alto, Calif) as described previously. 38 Monocytes were resuspended at a density of 1 ϫ 10 6 cells/mL, and the chemotaxis assay was performed using a 48-well migration chamber with a 5-m membrane (Millipore, Eschborn, Germany). The chemotaxis chamber was incubated for 90 minutes in a humidified cell incubator. Migrated cells were stained using a Hematocolor Set (Merck, Darmstadt, Germany) and counted at a 320-fold magnification. As a chemotaxis positive control, 1% human sera was used. 39 A minimum of three wells per experiment was used, and five high-power fields per well were counted. All experiments were performed in triplicate or quadruplicate. Results are given as the average number of migrated cells in the percentage of migratory response of control cells.
Histology and immunochemistry
Histological and immunohistochemical investigations were performed on paraffin sections from formalin-fixed and routinely processed tumor tissue. Serial 3-m sections from the equatorial plain of the totally extirpated and embedded tumors were stained with hematoxylin and eosin. Macrophages were detected using the monoclonal Ab MAC-3 (PharMingen, Hannover, Germany). Labeled macrophages were visualized through incubation with a biotinylated secondary Ab, followed by addition of streptavidin-coupled alkaline phosphatase and amino-ethyl-carbazole (Aldrich-Chemie, Deisenhofen, Germany) as a substrate.
RESULTS
Construction and selection of HPV16 E6/E7 antisense and ribozyme-expressing AAV-2 vector plasmids To express HPV16 antisense and ribozyme genes in cervical carcinoma cell lines using AAV-2 vectors, we constructed two types of plasmids bearing the ITRs of AAV-2 derived from vector plasmid psub201 ϩ . 28 In plasmid pAV-CMV, the human CMV immediate-early promoter was placed in front of a multiple cloning site followed by the SV40 late polyadenylation signal and splice site (Fig 1A) . To compensate for the required minimal size for optimal packaging of AAV-2 vectors, 40 a 1.46-kb fragment of PARP was cloned in front of the expression cassette. A second poly(A) signal was inserted behind the 5Ј-ITR of AAV-2 to prevent the possible expression of the PARP fragment by the cryptic promoter activity of the 5Ј-ITR observed by others. 41 In a second vector construct, pAV-K14, the cytokeratin 14 promoter 30 replaced the CMV promoter and the PARP fragment. A slightly modified multiple cloning site allowed the insertion of genes of interest. Two fragments of the HPV16 E6/E7 genes ( Fig 1B, E6 /E7 and E6*/E7) and three different ribozymes (Fig 1B, Rz1 , Rz6, and Rz4) were cloned into these vectors in antisense orientations to be expressed under the control of the CMV or the cytokeratin 14 promoter (as indicated in Fig 1C) .
The antisense and ribozyme genes were chosen by kinetic selection of fast-annealing antisense RNA species. 42 Using the HPV16 E6/E7 sequences, it became clear that full-length antisense RNA was the fastest annealing species, and among the ribozymes tested, the RNAs with full-length or nearly full-length 3Ј ends ( Fig  1B) showed faster reannealing than shorter ones. 43 To further select the most potent antisense or ribozyme construct, we established a proliferation assay for cervical carcinoma cell lines. The AAV-2 vector plasmids expressing the different antisense and ribozyme genes under the control of the CMV or the cytokeratin 14 promoter (Fig 1) were microinjected together with IgG into the nuclei of HPV16-transformed SiHa and CaSki cells; cell proliferation was measured using a BrdUlabeling protocol followed by double immunofluorescence detection of microinjected and proliferating cells. 35 Three types of controls were performed: (a) HPV16-negative C33a cells were injected with the same antisense and ribozyme constructs, (b) HPV16-positive cells were injected with ribozyme Rz4 in the sense orientation to measure the influence of the injections, and (c) proliferation of noninjected cells was analyzed. Figure 2 shows the mean values of proliferating cells injected with the different constructs from two independent experiments in comparison with the three controls. It is evident that all AAV vector plasmids expressing the E6/E7 antisense or ribozyme genes inhibited proliferation of both SiHa and CaSki cells in comparison with C33a cells and the sense and noninjected controls. Overall, the inhibition of cell proliferation by the antisense and ribozyme genes expressed under the control of the CMV promoter was slightly more effective (up to 80% inhibition of cell proliferation) than by expression under the control of the weaker cytokeratin 14 promoter (up to 60% inhibition). However, there was no significant difference between the effects of different antisense or ribozyme constructs. Based on these experiments, we selected the CMV-driven antisense E6/E7 and the ribozyme Rz6 constructs as candidate genes to test their influence on tumor formation in nude mice.
Preparation of MCP-1-expressing AAV-2 vector plasmids
Analogous to the antisense and ribozyme genes, we also cloned the human JE gene (encoding MCP-1) into the multiple cloning sites of the AAV-2 vectors pAV-CMV and pAV-K14 to express the protein under the control of the two different promoters (Fig 3A) . Expression of MCP-1 after transfection of the vector plasmids in HeLa cells was analyzed via Northern blots and a MCP-1 ELISA (Fig 3, B and C) . A specific transcript was detected in the Northern blots of RNAs from HeLa cells transfected with both the CMV-driven and the K14-driven expression construct, showing a reduced mobility in the gel due to the larger 3Ј-nontranslated portion of the JE gene in the vector constructs compared with the transcript of the endogenous gene in 444 cells. 44 As evidenced from the Northern blot analysis and the ELISA data, two different clones of the CMV-driven expression construct produced a 10-to 30-fold higher amount of MCP-1 than the K14-driven construct.
Infection of cervical carcinoma cells with rAAV-2 and expression of MCP-1
To establish defined infection conditions of cervical cancer cells with rAAV-2, we infected HeLa and SiHa cells with a rAAV expressing the lacZ gene under the control of the CMV promoter 36 and analyzed the transduction efficiency by histochemical staining. As shown in Figure 4 , a few SiHa cells were already transduced at an MOI of 1, increasing to ϳ35% of transduced cells at an MOI of 5 and 50% at an MOI of 10. Similar values were obtained after infection of HeLa cells (data not shown). Infection of SiHa cells with increasing MOIs of AAV-2 expressing MCP-1 under the control of the CMV promoter led to a MCP-1 expression that reached values of up to 4 g per mL of medium, and expression persisted for Ͼ5 days (Fig 5A) . Analysis of the chemotactic activity of the secreted MCP-1 also showed an MOIdependent increase and a prolonged persistence of chemotactic activity; however, with the supernatant of cells infected with lower MOIs, we observed a high variability in the results due to the lower sensitivity of this assay (Fig 5B) . Fig  6A) and reduced both the growth rate and the tumor volume of SiHa-derived tumors (Fig 6, B and C) . As expected from the previous results, this effect was not further enhanced upon coinfection of the cells with two AAV-2 vectors expressing MCP-1 or antisense E6/E7, respectively (data not shown).
In vivo injection of 5 ϫ 10 6 IU of MCP-1-expressing rAAV-2 into established tumors, followed by a second injection of 1 ϫ 10 7 U 5 days later led to a reduction in the mean growth rate of the tumors compared with controls (i.e., tumors that were injected with Hank's buffer) (Fig 7A) or rAAV-2 expressing antisense MCP-1 (data not shown). Sequential injection of the tumors with MCP-1 followed by ribozyme Rz6-expressing AAV-2 vectors resulted in the same reduction in tumor growth rate and did not provide an additional benefit (Fig 7A) .
Histological analysis of the tumors
In general, all tumors exhibited a similar morphology. Fig 1) were microinjected into the cell nuclei of SiHa cells or CaSki cells (both HPV16-positive). Cell proliferation was then measured by BrdU labeling and evaluation of the proliferating cells using an immunofluorescence assay as described in Materials and Methods. Controls included HPV16-negative C33a cells as well as cells injected with HPV16 E6/E7 sense expression constructs and noninjected cells. Each column represents the arithmetical mean from two independent sets of injections.
KUNKE, GRIMM, DENGER, ET AL: GENE THERAPY OF CERVICAL CARCINOMA area). The distribution of macrophages throughout these three regions was evaluated in sections obtained from tumors removed at different time points after rAAV vector treatment. Macrophages were detected using the MAC-3 Ab (Fig 7B) and quantified. The respective results are listed using a four degree scale (Table 1) .
Generally, a low or moderate accumulation of macrophages in the tumor and the perinecrotic area was observed, whereas at the capsule surface, an increased macrophage concentration was detected in rAAV MCP-1-treated tumors within the first 2 weeks; this concentration declined during the following weeks. Direct injection into the tumor led to moderate and high macrophage accumulation in the tumor or the perinecrotic area, respectively.
DISCUSSION
Treatment of cervical cancer on a molecular level seems possible due to the relatively well-established knowledge of the molecular etiology of this cancer. Here we describe a preclinical study that focused on two types of molecules obviously associated with the development of this cancer, the transforming genes E6 and E7 of HPV16 and the cellular cytokine MCP-1, in ex vivo and in vivo gene transfer protocols using the AAV-2 vector system. Although expression of different antisense and ribozyme genes with the AAV-2 vector system failed to show an antitumoral effect, transfer of the JE gene into tumor cells and expression of MCP-1 had a clear inhibitory effect on tumor growth. Among the molecules discussed as possible targets for gene therapy of cancers involving papillomaviruses, application of antisense or ribozyme molecules has a favored position because of their specificity and the requirement of continued expression of the transforming genes E6 and E7 for maintaining the malignant phenotype of cervical cancer cells. 45, 46 The effects of antisense plasmids or oligonucleotides on the cell proliferation of cervical cancer cell lines have already been demonstrated in a variety of assays. [7] [8] [9] 11, 12 However, for a therapeutic application of antisense genes, there is a delivery problem: a high percentage of target cells has to ϩ (TR), the polyadenylation signal (pA1) from pGL-2, the spacer fragment from PARP, the CMV immediate-early promoter (P CMV ), the cytokeratin 14 promoter (P K14 ), and the polyadenylation signal from SV40 (pA2) are indicated. The cDNA coding for human MCP (MCP-1/JE) was cloned behind the CMV or the cytokeratin 14 promoter, respectively. B: Expression of the MCP-1 gene was tested via transient transfection of the vector constructs into HeLa cells followed by Northern blot analysis. Expression of MCP-1 in the non-malignant HeLa-fibroblast hybrids 444 served as a positive control. Two independent pAV-CMV-MCP-1 clones (9-CMV and 4-CMV) were tested. MCP-1 mRNA derived from the AAV expression constructs migrated slower than the control mRNA due to a longer poly(A) signal. C: MCP-1 was detected via an ELISA using supernatants from HeLa cells transiently transfected with pAV-CMV-MCP-1 constructs (9-CMV, 4-CMV) or with pAV-K14-MCP-1 (14-K14). As a control, supernatants from 444 cells and HeLa cells were analyzed. The concentration of MCP-1 protein in the supernatants is given in nanograms per milliliter.
be transduced, because no bystander effect will help to spread the therapeutic principle. In addition, the expression of antisense genes has to be stable because the tumor cells are not eliminated by treatment with a proliferation-inhibiting antisense construct. We chose the AAV-2 vector system because of its efficiency with regard to the transduction of HeLa cells [47] [48] [49] and the potential of this vector to integrate and provide longterm expression of transgenes in a number of cell types in vivo. 50 -54 We expressed the therapeutic genes under the control of two different promoters, the CMV promoter and the cytokeratin 14 promoter. The CMV promoter provides very high expression levels of the transduced genes, which was confirmed by the expression analysis. The cytokeratin 14 promoter was expected to provide a long-term, tissue-specific expression of a transgene in the proliferating basal layer of epithelia, where cervical cancer development is expected to occur. Analysis of the vector constructs in a cell proliferation assay showed that the effects of the antisense and ribozyme genes expressed under the control of the CMV promoter were more efficient than under the control of the CK14 promoter. Therefore, we decided to first test the CMV-driven constructs in the animal experiments. Infection of SiHa and HeLa cells with rAAV reporter constructs suggested that Ͼ35% of the cells were transduced. However, because the cells were not additionally infected with adenovirus, a much higher number of cells contained the vector DNA, which could eventually lead to retarded but long-term expression of the transgene. 55 Nevertheless, no significant effect on tumor growth could be detected in the animal experiments after transduction with E6/E7 antisense or ribozyme-expressing rAAV vectors. There could be three reasons for this failure: (a) the conversion rate of actually transduced cells to transgene-expressing cells was too slow compared with the proliferation rate of the tumor cells, thus leading to a fast dilution of the vector DNA in the carcinoma cells; (b) the number of copies transduced by the vector system may have been too low to sufficiently suppress cell proliferation (e.g., even after injection of a high copy number of vector DNA only a maximum inhibition of proliferation of 80% was achieved); or (c) detectable tumors were visible at the earliest at ϳ20 days postimplantation of the tumor cells, which, however, is the time span where genes transferred into HeLa cells Supernatants were collected after 1, 2, or 5 days, and the MCP-1 concentration was determined using a MCP-1 ELISA (A) or chemotaxis assay (B) as described in Materials and Methods. Chemotactic activity is given as a percentage of standard chemotactic activity using 1% human sera.
using rAAV vectors lost Ͼ80% of their initially detected transgene expression (data not shown). This means that during the decline of rAAV-mediated gene expression, increasing numbers of cells could have started to proliferate again. Taking all these limitations into consideration, one can well understand that delivery of antisense or ribozyme genes with this vector system in this experimental setting did not lead to a therapeutic effect. This finding, however, contrasts with a report in which adenoviral vectors were used to transfer a similar antisense gene. 22 In this study, a complete inhibition of tumor formation in nude mice was observed when SiHa cells were infected with a recombinant adenovirus at an MOI of 30 expressing the antisense gene under the control of the CMV promoter. This result is even more surprising because the applied MOI led to an inhibition of SiHa cell proliferation of only ϳ60%. Also a repeated direct injection of phosphorothioate oligonucleotides into established tumors 21 formulated with liposomes showed a higher efficiency than the AAV-2 vector system, suggesting that AAV-2 is not the vehicle of choice for an antisense therapy. 23 In contrast to these results, transduction of the JE gene into SiHa or HeLa cells by AAV-2 vectors was sufficient to achieve a significant reduction in tumor growth. This reduction was specific for the expression of the MCP-1 gene, because transduction of the lacZ gene or antisense MCP-1 showed no significant effects on tumor growth. Analysis of the time course of tumor growth derived from implanted SiHa cells suggests that tumor growth is nearly completely suppressed at ϳ40 -45 days after the implantation of the tumor cells. These results confirm and extend experiments performed with HeLa cell lines, which were stably transfected with a plasmid constitutively expressing the JE gene. 44 However, in these stably MCP-1-expressing tumor cells (HeLa), tumor development was also not completely suppressed. This escape from tumor suppression could in both cases be due to local differences in MCP-1 concentration or to a non-homogeneous infiltration of the tumor by macrophages. However, in the case of rAAV-mediated JE gene transfer, this escape might also be attributed to the already mentioned decline in MCP-1 expression after rAAV infection. Our findings are also in line with a number of reports in which it was shown for several other tumor cell lines that stable ectopic expression of the JE gene or cocultivation with JE-expressing fibroblasts stimulates tumor necrosis, recruits macrophages into tumors in nude mice, suppresses the metastatic potential, and even leads to a suppression of tumor growth. 56 -61 Perhaps a combination of this tumor growth-reducing effect of MCP-1 with other tumoristatic treatments (e.g., suicide genes, immunomodulatory genes (for example, genes activating macrophages), or lipopolysaccharides 62 may improve the observed therapeutic effect of MCP-1 on cervical carcinoma tumor formation.
In this report, we show that transduction of the JE gene with rAAV vectors into a limited number of cells can reach therapeutically reasonable levels of the transgene, leading to significantly reduced growth of HeLaand SiHa-derived tumors in nude mice. This first report of viral vector-mediated transfer of the JE gene into tumor cells provides a basis for a potential therapeutic application of this gene in tumor treatment. 
